Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
11:43:16 EDT Wed 24 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:INCY from 2023-04-25 to 2024-04-24 - 40 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-23 07:00U:INCYNews ReleaseIncyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
2024-04-11 08:00U:INCYNews ReleaseIncyte to Report First Quarter Financial Results
2024-04-01 08:30U:INCYNews ReleaseIncyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
2024-03-29 16:30U:INCYNews ReleaseIncyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-03-10 16:05U:INCYNews ReleaseIncyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura(TM)) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
2024-03-10 16:05U:INCYNews ReleaseIncyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
2024-03-04 08:00U:INCYNews ReleaseNew Data from Incyte's Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
2024-02-29 10:19U:INCYNews ReleaseIncyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients' Lives through Generative AI
2024-02-29 07:30U:INCYNews ReleaseKnight Therapeutics Announces Launch of Minjuvi(TM) in Brazil
2024-02-27 16:08U:INCYNews ReleaseIncyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
2024-02-15 08:00U:INCYNews ReleaseIncyte to Present at Upcoming Investor Conference
2024-02-13 07:00U:INCYNews ReleaseIncyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
2024-02-05 16:46U:INCYNews ReleaseIncyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi ‚ ®)
2024-01-23 08:00U:INCYNews ReleaseIncyte to Report Fourth Quarter and Year-End 2023 Financial Results
2024-01-08 08:30U:INCYNews ReleaseIncyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-12 08:00U:INCYNews ReleaseIncyte to Present at Upcoming Investor Conferences
2023-11-02 09:00U:INCYNews ReleaseIncyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
2023-10-31 07:00U:INCYNews ReleaseIncyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
2023-10-18 08:00U:INCYNews ReleaseIncyte to Present at Upcoming Investor Conferences
2023-10-16 08:00U:INCYNews ReleaseIncyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023
2023-10-13 10:30U:INCYNews ReleaseIncyte Announces New Data for Ruxolitinib Cream (Opzelura ‚ ®) in Children with Atopic Dermatitis
2023-10-13 08:00U:INCYNews ReleaseData From Incyte ¢ € ™s Povorcitinib Clinical Program to Be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)
2023-10-12 09:00U:INCYNews ReleaseGlobal CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
2023-10-11 10:30U:INCYNews ReleaseNew Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura ‚ ® (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients
2023-10-11 09:15U:INCYNews ReleaseIncyte and Mandy Moore Partner to Empower People with Atopic Dermatitis to Find Their Moments of Clarity
2023-10-11 08:15U:INCYNews ReleaseIncyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
2023-10-10 16:45U:INCYNews ReleaseKnight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil
2023-10-10 08:00U:INCYNews ReleaseIncyte to Report Third Quarter Financial Results
2023-09-29 13:43U:INCYNews ReleaseIncyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress
2023-08-22 08:00U:INCYNews ReleaseIncyte to Present at Upcoming Investor Conferences
2023-08-01 07:00U:INCYNews ReleaseIncyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
2023-07-31 16:01U:INCYNews ReleaseReplimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
2023-07-24 07:00U:INCYNews ReleaseSyndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease
2023-07-11 16:05U:INCYNews ReleaseIncyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib Cream (Opzelura ‚ ®) in Children with Atopic Dermatitis
2023-07-11 08:00U:INCYNews ReleaseIncyte to Report Second Quarter Financial Results
2023-05-25 17:01U:INCYNews ReleaseData from Across Incyte ¢ € ™s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress
2023-05-23 08:00U:INCYNews ReleaseIncyte to Present at Upcoming Investor Conferences
2023-05-08 08:30U:INCYNews ReleaseIncyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role
2023-05-02 07:00U:INCYNews ReleaseIncyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
2023-05-01 15:00U:INCYNews ReleaseIncyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura ‚ ® (ruxolitinib) Cream